Premium
Anaphylaxis following the use of a plasma‐derived immunopurified Monoclate‐P®, and the recombinant Recombinate® and Kogenate® factor VIII: a therapeutic challenge
Author(s) -
PERNOD G.,
ARMARI C.,
BARRO C.,
PLANTAZ D.,
CAPERAN D.,
JACQUOT C.,
POLACK B.
Publication year - 1999
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1046/j.1365-2516.1999.t01-1-00293.x
Subject(s) - medicine , anaphylaxis , desensitization (medicine) , recombinant dna , anaphylactic shock , drug , pharmacology , plasma levels , shock (circulatory) , immunology , allergy , receptor , biochemistry , chemistry , gene
We report the first case of an anaphylactic shock to three different FVIII concentrates, one immuopurified plasma‐derived (Monoclate‐P®) and two recombinant FVIII products (Recombinate® and Kogenate®). These shocks appeared despite the use of antihistaminic drugs. The use of a highly purified plasma‐derived FVIII allowed successful on‐demand therapy without any antiallergic drug or desensitization.